OncoMatch/Clinical Trials/NCT07270835
Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma
Is NCT07270835 recruiting? Yes, currently enrolling (Jun 2026). This Phase 4 trial studies multiple treatments including Rituximab and Zanubrutinib for hemophagocytic lymphohistiocytosis.
Treatment: Rituximab · Zanubrutinib — For patients who met the inclusion criteria, treatment regimens were administered: Rituximab 375 mg/m², intravenously, once weekly for 4 weeks. Zanubrutinib 160 mg, orally, twice daily for 4 weeks. Combined drugs: prednisone 100 mg/m²/d, orally, d1-5; Ruxolitinib 15mg bid orally; With/without emapalumab as appropriate.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: MS4A1 CD20-positive (increased proportion of CD20-positive B cells by bone marrow flow cytometry)
HLH patients whose bone marrow flow cytometry show an increased proportion of CD20-positive B cells
Demographics
Prior therapy
Cannot have received: experimental drugs
Exception: had not completed the drug washout period
Have received other experimental drugs and had not completed the drug washout period
Lab requirements
Blood counts
Fibrinogen could be corrected to ≥0.6g/L by infusion
Kidney function
Baseline serum creatinine ≤1.5 times ULN; CrCl <30 mL/min or severe renal insufficiency [excluded]
Liver function
ALT or AST >5 times the upper limit, or severe cirrhosis [excluded]
Cardiac function
Left ventricular ejection fraction (LVEF) ≥50% measured by echocardiography; NYHA class III-IV heart failure or severe arrhythmia [excluded]
Baseline serum creatinine ≤1.5 times ULN; Fibrinogen could be corrected to ≥0.6g/L by infusion; Left ventricular ejection fraction (LVEF) ≥50% measured by echocardiography; Severe organ dysfunction including NYHA class III-IV heart failure or severe arrhythmia; Liver function: ALT or AST >5 times the upper limit, or severe cirrhosis; Renal function: CrCl <30 mL/min or severe renal insufficiency
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07270835 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior experimental drugs disqualifies patients from enrollment.
Does this trial require MS4A1?
Yes, MS4A1 CD20-positive is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 80 years or younger and at least 14 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages